RecruitingNot ApplicableNCT07557706

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

Sponsor

University of Alabama at Birmingham

Enrollment

24 participants

Start Date

Sep 15, 2025

Study Type

INTERVENTIONAL

Conditions

PARKINSON DISEASE (Disorder)

Summary

The purpose of this study is to find out whether a type of gentle nerve stimulation, called transcutaneous auricular Vagus Nerve Stimulation (taVNS), can help improve how the body regulates heart rate and blood pressure in people with Parkinson's Disease (PD). Problems with heart rate and blood pressure control are common and can make it harder for people to exercise or do daily activities. By using this non-invasive form of nerve stimulation and testing how it affects the body's natural responses, this study hopes to learn if taVNS could be a helpful tool to support physical therapy and improve overall function.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

Diagnosis of idiopathic PD
Stable medication for at least 4 weeks prior to the study

Exclusion Criteria9

Use of beta blockers
Sustained severe hypertension (>/= 180/110 mmHg while seated)
Significant uncontrolled cardiac arrhythmia
Unstable angina
Congestive heart failure
History of myocardial infarction
History of seizures
Severe cognitive impairment
Pregnant women or women who are planning to become pregnant

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEtranscutaneous auricular vagus nerve stimulation

Participants will sit quietly while receiving active nerve stimulation for 15 minutes. A gentle electrical current is delivered through hydrogel electrodes placed in the ear. The active stimulation parameters are set to 30 Hz, 250 µs, and 0.1-4 mA.